It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Metastatic Triple Negative Breast Cancer Treatment Study

Clinical Trial Title: 
A phase III, multicenter, randomized placebo-controlled study of atezolizumab (MPDL3280A) in combination with nab paclitaxel compared with placebo with nab paclitaxel for patients with Previously untreated metastatic triple negative breast cancer.
Clinical Trial Protocol ID: 
16011109
Clinical Trial Investigator Name: 
Ruta D. Rao, MD
Clinical Trial Protocol Description: 

This study is being conducted to test atezolizumab in combination with nab-paclitaxel in treating participants with metastatic breast cancer. Subjects will receive either atezolizumab or placebo on days 1 and 15 plus nab-paclitaxel on days 1, 8 and 15 of a 28-day cycle.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Be a metastatic or inoperable locally advanced TNBC patient who has not received prior systemic cytotoxic therapy for mBC.
  • Have completed any prior neoadjuvant or adjuvant treatment at least 12 months prior to randomization.

You will be excluded from the study if any of the following criteria apply to you:

  • Have a history of idiopathic pulmonary fibrosis and any pneumonitis, including drug induced (fibrosis in RT field is permitted).
  • Have a history of autoimmune disease.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Breast Cancer
Contact Phone: 
(312) 942-3732
Contact Name: 
Chrystie Paul, RN, BSN